Amphastar Pharmaceuticals Resultados de beneficios anteriores
Pasado controles de criterios 6/6
Amphastar Pharmaceuticals ha aumentado sus beneficios a una tasa media anual de 42.1%, mientras que los beneficios de la industria de Pharmaceuticals han experimentado un crecimiento de 1.7% anual. Los ingresos han ido creciendo a una tasa media de 15.1% al año. La rentabilidad financiera de Amphastar Pharmaceuticals es de 21.5%, y sus márgenes netos son de 21.3%.
Información clave
40.2%
Tasa de crecimiento de los beneficios
39.4%
Tasa de crecimiento del BPA
Crecimiento de la industria Pharmaceuticals | 6.0% |
Tasa de crecimiento de los ingresos | 16.0% |
Rentabilidad financiera | 23.0% |
Margen neto | 22.9% |
Última actualización de beneficios | 31 Mar 2024 |
Actualizaciones de resultados anteriores recientes
Recent updates
Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet
Mar 27Why Amphastar Pharmaceuticals Is A Strong Buy: Growth, Valuation, And Strategic Acquisitions
Mar 04Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today
Jan 04Why Investors Shouldn't Be Surprised By Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) P/E
Dec 20Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Rock Solid Balance Sheet
Dec 03Amphastar Pharmaceuticals (NASDAQ:AMPH) Ticks All The Boxes When It Comes To Earnings Growth
Sep 18An Intrinsic Calculation For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Suggests It's 35% Undervalued
Sep 03These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely
Aug 17Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Well Worth Watching
Jun 02We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease
May 11Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Intrinsic Value Is Potentially 51% Above Its Share Price
Mar 02Is Now The Time To Put Amphastar Pharmaceuticals (NASDAQ:AMPH) On Your Watchlist?
Feb 07Does Amphastar Pharmaceuticals (NASDAQ:AMPH) Have A Healthy Balance Sheet?
Jan 24Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors
Nov 02Amphastar: A Pharmaceutical Growth Stock
Oct 06Amphastar wins FDA approval for Epinephrine pre-filled syringes
Aug 16Amphastar Pharmaceuticals: Compelling Growth Prospects For H2 2022 And Beyond
Aug 08Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?
Jul 24Amphastar generic vasopressin for increasing blood pressure gets FDA approval
Jul 19We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease
Jun 10Amphastar Pharmaceuticals: Stock With An Attractive 6 To 1 Risk-Reward Ratio
May 13I Ran A Stock Scan For Earnings Growth And Amphastar Pharmaceuticals (NASDAQ:AMPH) Passed With Ease
Apr 23These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely
Feb 13Amphastar Pharma: A Well-Run, Diversified Mid Cap
Jan 26Should You Be Adding Amphastar Pharmaceuticals (NASDAQ:AMPH) To Your Watchlist Today?
Jan 08Desglose de ingresos y gastosBeta
Cómo gana y gasta dinero Amphastar Pharmaceuticals. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
---|---|---|---|---|
31 Mar 24 | 676 | 155 | 85 | 71 |
31 Dec 23 | 644 | 138 | 80 | 74 |
30 Sep 23 | 601 | 135 | 75 | 71 |
30 Jun 23 | 541 | 102 | 72 | 72 |
31 Mar 23 | 519 | 93 | 69 | 78 |
31 Dec 22 | 499 | 91 | 67 | 75 |
30 Sep 22 | 485 | 77 | 63 | 75 |
30 Jun 22 | 477 | 91 | 62 | 67 |
31 Mar 22 | 455 | 81 | 65 | 62 |
31 Dec 21 | 438 | 62 | 67 | 61 |
30 Sep 21 | 413 | 36 | 68 | 62 |
30 Jun 21 | 384 | 10 | 67 | 69 |
31 Mar 21 | 368 | 2 | 69 | 67 |
31 Dec 20 | 350 | 1 | 63 | 67 |
30 Sep 20 | 337 | 7 | 63 | 69 |
30 Jun 20 | 334 | 4 | 62 | 70 |
31 Mar 20 | 327 | 52 | 58 | 70 |
31 Dec 19 | 322 | 49 | 63 | 69 |
30 Sep 19 | 329 | 52 | 66 | 66 |
30 Jun 19 | 324 | 53 | 67 | 59 |
31 Mar 19 | 316 | 2 | 65 | 58 |
31 Dec 18 | 295 | -6 | 58 | 58 |
30 Sep 18 | 265 | -7 | 52 | 52 |
30 Jun 18 | 248 | -9 | 51 | 51 |
31 Mar 18 | 242 | -4 | 51 | 46 |
31 Dec 17 | 240 | 4 | 51 | 44 |
30 Sep 17 | 243 | 0 | 52 | 44 |
30 Jun 17 | 250 | 4 | 51 | 44 |
31 Mar 17 | 252 | 9 | 48 | 44 |
31 Dec 16 | 255 | 10 | 47 | 42 |
30 Sep 16 | 269 | 21 | 45 | 38 |
30 Jun 16 | 268 | 14 | 43 | 39 |
31 Mar 16 | 254 | 0 | 45 | 39 |
31 Dec 15 | 252 | -3 | 44 | 37 |
30 Sep 15 | 230 | -13 | 45 | 36 |
30 Jun 15 | 226 | -15 | 46 | 34 |
31 Mar 15 | 221 | -10 | 43 | 29 |
31 Dec 14 | 210 | -11 | 40 | 29 |
30 Sep 14 | 209 | -6 | 38 | 28 |
30 Jun 14 | 209 | -1 | 38 | 29 |
31 Mar 14 | 223 | 8 | 36 | 30 |
31 Dec 13 | 230 | 12 | 36 | 33 |
30 Sep 13 | 227 | 14 | 35 | 33 |
Ingresos de calidad: AMPH tiene ganancias de alta calidad.
Margen de beneficios creciente: Los actuales márgenes de beneficio (21.3%) de AMPH son superiores a los del año pasado (18.3%).
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: En los últimos 5 años, los beneficios de lAMPH han crecido significativamente en un 40.2% al año.
Acelerando crecimiento: El crecimiento de los beneficios de AMPH en el último año (50.5%) supera su media de 5 años (42.1% al año).
Beneficios vs. Industria: El crecimiento de los beneficios de AMPH en el último año (50.5%) superó al de la industria Pharmaceuticals -6.8%.
Rentabilidad financiera
Alta ROE: La rentabilidad financiera (21.5%) de AMPH se considera alta.